Major Drugs - Pittsburgh, PA, US
Right now, 60-80% of patients show little response to standard immunotherapy or chemotherapy. Duo Oncology plans to transform patient outcomes with a new type of nanotherapy.
Gmail
Varnish
Wix
Mobile Friendly
Google Cloud Hosting